A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

ClinicalTrials.gov ID: NCT06365853

Public ClinicalTrials.gov record NCT06365853. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 9, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Study identification

NCT ID: NCT06365853
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AbbVie; Industry
Enrollment: 100 participants

Conditions and interventions

Conditions

Interventions

Brimonidine tartrate ophthalmic solution eye drops Drug
Lubricating Eye Drops Drug
Mirvetuximab Soravtansine Drug
Prednisolone acetate ophthalmic suspension 1% eye drops Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 28, 2024
Primary completion: May 31, 2026
Completion: May 31, 2027
Last update posted: Mar 24, 2026

2024 – 2027

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
University of California Los Angeles /ID# 269339	Los Angeles	California	90095	Recruiting
Norton Cancer Institute - St. Matthews /ID# 269070	Louisville	Kentucky	40207	Completed
Holy Cross Hospital - Silver Spring /ID# 269344	Silver Spring	Maryland	20910	Recruiting
Mercy David C. Pratt Cancer Center /ID# 269350	St Louis	Missouri	63141	Recruiting
The Center Of Hope /ID# 269348	Reno	Nevada	89511	Active, not recruiting
Holy Name Medical Center /ID# 269340	Teaneck	New Jersey	07666	Recruiting
New York Oncology Hematology - Albany Cancer Center /ID# 269345	Albany	New York	12206-5013	Completed
Women'S Cancer Care Associates /ID# 269980	Albany	New York	12208	Completed
Duke Cancer Institute /ID# 269342	Durham	North Carolina	27710	Recruiting
Summa Health /ID# 269349	Akron	Ohio	44304-1407	Recruiting
UT Southwestern Medical Center /ID# 269341	Dallas	Texas	75390	Recruiting
Memorial Hermann Southeast Hospital /ID# 269347	Houston	Texas	77089	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06365853, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 24, 2026 · Synced May 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06365853 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →